Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ECOR NASDAQ:MBAI NYSE:NSPR NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.67+11.4%$6.37$4.16▼$8.64$55.36M0.6868,669 shs129,632 shsMBAICheck-Cap$1.78-4.3%$1.68$0.59▼$3.92$12.98M0.571.64 million shs47,647 shsNSPRInspireMD$1.00-2.9%$1.39$0.97▼$2.93$46.84M0.82181,136 shs51,911 shsPSTVPlus Therapeutics$6.59-4.4%$5.74$2.90▼$23.42$45.34M1.4397,748 shs127,930 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore-2.28%-6.84%-3.39%-4.16%+21.75%MBAICheck-Cap+1.64%+3.91%+13.90%+12.73%+185,999,900.00%NSPRInspireMD+3.00%-9.65%-22.56%-43.09%-53.60%PSTVPlus Therapeutics+7.15%+19.62%-3.50%+0.22%-18.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.67+11.4%$6.37$4.16▼$8.64$55.36M0.6868,669 shs129,632 shsMBAICheck-Cap$1.78-4.3%$1.68$0.59▼$3.92$12.98M0.571.64 million shs47,647 shsNSPRInspireMD$1.00-2.9%$1.39$0.97▼$2.93$46.84M0.82181,136 shs51,911 shsPSTVPlus Therapeutics$6.59-4.4%$5.74$2.90▼$23.42$45.34M1.4397,748 shs127,930 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore-2.28%-6.84%-3.39%-4.16%+21.75%MBAICheck-Cap+1.64%+3.91%+13.90%+12.73%+185,999,900.00%NSPRInspireMD+3.00%-9.65%-22.56%-43.09%-53.60%PSTVPlus Therapeutics+7.15%+19.62%-3.50%+0.22%-18.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECORelectroCore 2.00Hold$18.00170.92% UpsideMBAICheck-Cap 1.00SellN/AN/ANSPRInspireMD 3.00Buy$4.50341.18% UpsidePSTVPlus Therapeutics 2.43Hold$58.00758.37% UpsideCurrent Analyst Ratings BreakdownLatest MBAI, ECOR, NSPR, and PSTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026MBAICheck-Cap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$475.00 ➝ $65.003/31/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/27/2026ECORelectroCore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ECORelectroCore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/19/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.002/24/2026NSPRInspireMD Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.002/24/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECORelectroCore$32.03M1.72N/AN/A($0.69) per share-9.63MBAICheck-CapN/AN/A$0.55 per share3.22$0.47 per shareN/ANSPRInspireMD$10.85M4.40N/AN/A$1.83 per share0.56PSTVPlus Therapeutics$5.21M8.92N/AN/A$1.74 per share3.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECORelectroCore-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%8/5/2026 (Estimated)MBAICheck-Cap$4.14M-$2.77N/AN/AN/AN/AN/AN/AN/ANSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/APSTVPlus Therapeutics-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%5/29/2026 (Estimated)Latest MBAI, ECOR, NSPR, and PSTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026PSTVPlus Therapeutics-$0.8480N/AN/AN/A$0.97 millionN/A5/15/2026Q1 2026PSTVPlus Therapeutics-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million5/6/2026Q1 2026ECORelectroCore-$0.59-$0.59N/A-$0.59$9.01 million$9.58 million3/19/2026Q4 2025ECORelectroCore-$0.35-$0.34+$0.01-$0.34$9.09 million$9.24 million3/12/2026Q4 2025PSTVPlus Therapeutics-$0.03$6.25+$6.28N/A$1.23 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthECORelectroCoreN/AN/AN/AN/AN/AMBAICheck-CapN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECORelectroCoreN/A1.020.86MBAICheck-CapN/A0.050.05NSPRInspireMDN/A6.396.05PSTVPlus TherapeuticsN/A2.271.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECORelectroCore26.74%MBAICheck-Cap1.07%NSPRInspireMD44.78%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipECORelectroCore13.80%MBAICheck-Cap0.48%NSPRInspireMD34.06%PSTVPlus Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECORelectroCore508.30 million7.15 millionNot OptionableMBAICheck-Cap807.29 million7.25 millionN/ANSPRInspireMD5046.84 million18.33 millionOptionablePSTVPlus Therapeutics206.88 million6.71 millionNot OptionableMBAI, ECOR, NSPR, and PSTV HeadlinesRecent News About These CompaniesPlus Therapeutics (PSTV) to Release Earnings on FridayMay 22 at 1:10 AM | americanbankingnews.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Given Consensus Recommendation of "Hold" by AnalystsMay 20 at 4:19 AM | americanbankingnews.comPlus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS OncologyMay 19 at 7:30 AM | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Shares Up 11.2% - What's Next?May 19 at 2:16 AM | americanbankingnews.comPlus Therapeutics Stockholders Back Directors and Incentive PlanMay 15, 2026 | tipranks.comPlus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2026 | zacks.comPlus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial RolloutMay 15, 2026 | globenewswire.comForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6May 14, 2026 | 247wallst.comAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Charles River Labs (CRL)May 14, 2026 | theglobeandmail.comPlus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in ...May 8, 2026 | markets.businessinsider.comPlus Therapeutics Presents Promising Phase 1 ReSPECT-LM Trial Data for REYOBIQ™ at AANS Annual Scientific MeetingMay 8, 2026 | quiverquant.comQPlus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal MetastasesMay 8, 2026 | globenewswire.comPlus Therapeutics Receives Medicare Enrollment Approval for CNSide DiagnosticMay 7, 2026 | globenewswire.comPlus Therapeutics (PSTV) price target decreased by 72.34% to 38.76April 29, 2026 | msn.comPlus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerApril 28, 2026 | globenewswire.comPlus Therapeutics Inc.: Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQApril 24, 2026 | finanznachrichten.dePlus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™April 23, 2026 | globenewswire.comPlus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 22, 2026 | globenewswire.comPlus Therapeutics Regains Nasdaq Listing Compliance After Reverse SplitApril 22, 2026 | theglobeandmail.comPlus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesVerizon’s Signal Strength: The Turnaround Call Is Loud and ClearBy Jeffrey Neal Johnson | April 30, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 2026Berkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Verizon Q1 Earnings Dip—A Buying Opportunity for VZ Stock?By Thomas Hughes | April 28, 2026GE Vernova Beats Earnings by 790% as Data Center Demand ExplodesBy Chris Markoch | April 23, 2026MBAI, ECOR, NSPR, and PSTV Company DescriptionselectroCore NASDAQ:ECOR$6.67 +0.68 (+11.35%) Closing price 04:00 PM EasternExtended Trading$6.62 -0.05 (-0.75%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Check-Cap NASDAQ:MBAI$1.78 -0.08 (-4.30%) Closing price 04:00 PM EasternExtended Trading$1.78 0.00 (0.00%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.InspireMD NYSE:NSPR$1.00 -0.03 (-2.91%) Closing price 04:00 PM EasternExtended Trading$1.00 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Plus Therapeutics NASDAQ:PSTV$6.59 -0.30 (-4.35%) Closing price 04:00 PM EasternExtended Trading$6.70 +0.11 (+1.67%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
